Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-48. (Cancelled).

49. (Previously Presented) A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;

storing the anti-bradycardia pacing energy; and

delivering the anti-bradycardia pacing energy to the patient's heart;

wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately 25 volts and approximately 50 volts.

50. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately .1 volts and approximately 100 volts.

51. (Previously Presented) The method of claim 50, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately .1 volts and approximately 25 volts.

52. (Previously Presented) The method of claim 50, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately 25 volts and approximately 50 volts.

53. (Previously Presented) A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;

storing the anti-bradycardia pacing energy; and

delivering the anti-bradycardia pacing energy to the patient's heart;

wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately 50 volts and approximately 75 volts.

54. (Previously Presented) A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;

storing the anti-bradycardia pacing energy; and

delivering the anti-bradycardia pacing energy to the patient's heart;

wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately 75 volts and approximately 100 volts.

55. (Previously Presented) A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;

storing the anti-bradycardia pacing energy; and

delivering the anti-bradycardia pacing energy to the patient's heart;

wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between 1 millisecond and approximately 40 milliseconds.

56. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between approximately 2 milliseconds and approximately 10 milliseconds.

57. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between approximately 10 milliseconds and approximately 20 milliseconds.

58. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between approximately 20 milliseconds and approximately 30 milliseconds.

59. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between approximately 30 milliseconds and approximately 40 milliseconds.

60. (Original) The method of claim 49, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.

61. (Previously Presented) The method of claim 60, wherein the positive voltage portion has a tilt of between approximately 5% and approximately 95%.

62. (Original) The method of claim 61, wherein the tilt is approximately 50%.

63. (Previously Presented) The method of claim 49, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is provided at a rate of between approximately 20 and approximately 120 stimuli/minute.

64. (Original) The method of claim 63, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.

65. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the third and fifth ribs.

66. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the fourth and sixth ribs.

67. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the sixth and eighth ribs.

68. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the eighth and tenth ribs.

69. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the tenth and twelfth ribs.